Drugs / CT-0525
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06254807 | Jan 2024 → Mar 2025 | — | Carisma Therapeutics Inc | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2024-06-25 | Carisma Therapeutics Inc | Regulatory Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors carismatx.com ↗
the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for CT-0525 |
| 2023-11-28 | Carisma Therapeutics Inc | Regulatory Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte carismatx.com ↗
Having received a Study May Proceed notification from the FDA, Carisma expects to initiate a Phase 1 study in the coming months and to treat the first patient in the first half of 2024. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-06-25 | Carisma Therapeutics Inc | Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors carismatx.com ↗ |
| 2024-05-16 | Carisma Therapeutics Inc | Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte carismatx.com ↗ |
| 2023-11-28 | Carisma Therapeutics Inc | Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte carismatx.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT-0525 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06254807 ↗ |
| Modality | Cell therapy | “Autologous monocyte engineered to contain an anti-HER2 chimeric antigen receptor” NCT06254807 ↗ |
| Route | Intravenous | “single IV administration of CT-0525 (3 billion CAR positive cells) on Day 1” NCT06254807 ↗ |